The study of Fibrin levels in Alzheimer's and related Dementias subjects Using 64Cu-FBP8 PET

The research company Massachusetts General Hospital is conducting the clinical trial Assess Fibrin in Brains With AD/ADRD.

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

It is planned to include 30 participants.

Actual study start date is March 29, 2022. The researchers expect to complete the study by September 28, 2022.

One primary outcome measure is Concentration of fibrin in the brains of ADRD subjects and healthy controls, 64Cu-FBP8-PET will be used to quantify brain fibrin content in the brains of ADRD subjects and healthy controls to evaluate potential regional differences.

Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT05336695